In addition, Yati and colleagues reveled that doxorubicin treatment stimulated the release of EVs in osteosarcoma, and the recipient cells acquired chemotherapeutic resistance by the activation of IL-1/PD-L1 signaling [54]. The gene discussed is CD274; the disease is osteosarcoma.